Detalles de la búsqueda
1.
Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.
Eur Urol
; 83(6): 497-504, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35999119
2.
Sleep patterns and sleep deprivation recorded by actigraphy in 4th-grade and 5th-grade students.
Sleep Med
; 67: 191-199, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31935621
3.
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy.
Eur Urol Focus
; 6(5): 999-1005, 2020 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30738795
4.
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
J Clin Oncol
; 35(1): 48-55, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28034079
5.
Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer.
JAMA Oncol
; 2(10): 1303-1309, 2016 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27254750
6.
Reply to Pontus Eriksson, Gottfrid Sjödahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed: Protein Expression to Predict Outcome to Targeted Therapy in Bladder Cancer: Too Little, Too Late?
Eur Urol
; 72(5): e137-e138, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28606457
Resultados
1 -
6
de 6
1
Próxima >
>>